SCHEMBL10088976

SCHEMBL10088976

O=C(O)c1ccc(OC2CC2)c(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.49
SCD O00767 2/20 0.47
PDE4D Q08499 3/20 0.46
PDE4A P27815 2/20 0.46
PDE4B Q07343 2/20 0.46
PDE4C Q08493 2/20 0.46
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
EPHX2 P34913 4/20 0.45
RAF1 P04049 1/20 0.45
MRGPRX4 Q96LA9 2/20 0.43
RBP4 P02753 1/20 0.43
TTR P02766 1/20 0.43
DDR1 Q08345 1/20 0.42
SRD5A2 P31213 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1918753 0.94 PDE4D (0.53) SYKSCDPDE4DPDE4APDE4B
SCHEMBL4949683 0.93 PDE4D (0.52) SYKSCDPDE4DPDE4APDE4B
SCHEMBL2313914 0.88 KDM4E (0.55) SYKSCDRAF1RBP4TTR
SCHEMBL31352699 0.84 NOTUM (0.54) SYKPDE4DEPHX2MRGPRX4RBP4
SCHEMBL4233582 0.81 SLC6A5 (0.46) SCDPDE4DPDE4APDE4BPDE4C
SCHEMBL16339979 0.81 EGFR (0.46) SYKSCDPDE4DPDE4APDE4B
SCHEMBL18031251 0.80 PDE4B (0.56) PDE4DPDE4APDE4BPDE4CEPHX2
SCHEMBL1918596 0.80 PDE4D (0.49) SYKPDE4DPDE4APDE4BPDE4C
SCHEMBL2617366 0.80 RORC (0.56) PDE4DPDE4APDE4BPDE4CEPHX2
SCHEMBL22077874 0.79 PDE4D (0.56) SYKPDE4DPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2012-07-12 US disclosed
US-8193378-B2 2H-chromene compound and derivative thereof ASTELLAS PHARMA INC. (JP) 2012-06-05 US disclosed
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2011-09-22 US disclosed
WO-2010064707-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF アステラス製薬株式会社 (JP) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, CCR1 SYK 436/4885SCD 972/4885PDE4D 1065/4885
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, S1PR4 SYK 569/4885SCD 679/4885PDE4D 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.